Renaissance Technologies LLC lifted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 7.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 525,500 shares of the company's stock after buying an additional 36,100 shares during the quarter. Renaissance Technologies LLC owned about 1.09% of Amphastar Pharmaceuticals worth $19,512,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Smartleaf Asset Management LLC boosted its stake in Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after acquiring an additional 493 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after buying an additional 871 shares during the last quarter. Huntington National Bank boosted its stake in shares of Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock valued at $50,000 after buying an additional 361 shares in the last quarter. TD Private Client Wealth LLC grew its holdings in Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after purchasing an additional 388 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock worth $80,000 after buying an additional 650 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on AMPH. Piper Sandler decreased their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th.
Read Our Latest Stock Analysis on AMPH
Amphastar Pharmaceuticals Stock Down 3.8 %
Shares of AMPH stock traded down $0.92 during mid-day trading on Tuesday, reaching $23.50. 779,923 shares of the company were exchanged, compared to its average volume of 458,899. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $22.60 and a fifty-two week high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company has a market capitalization of $1.12 billion, a P/E ratio of 7.83, a P/E/G ratio of 2.19 and a beta of 0.79. The business's 50 day simple moving average is $28.51 and its 200 day simple moving average is $37.90.
Insider Transactions at Amphastar Pharmaceuticals
In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 27.10% of the company's stock.
About Amphastar Pharmaceuticals
(
Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
See Also
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
